Hier auf Englisch:
Ich wuerde mich freuen, wenn jemand hier Erfahrung mit diesem Insulin hat und sie beschreiben wuerde (Akromegalie-Miezen?).
ACVIM 2019: https://www.eventscribe.com/2019/ACVIM/
EN04 - Comparison of Pharmacodynamics Between Insulin Glargine 100U/mL and Insulin Glargine 300U/mL in Healthy Cats
Chen Gilor, DVM, PhD, DACVIM
Associate Professor, UC Davis, Davis, California
In people, insulin glargine (IGla) 300U/mL (Toujeo®) is associated with longer duration of action (TDA) and lesser within-day variability compared to IGla 100U/mL (Lantus®). We hypothesized that compared to Lantus®, Toujeo® would have a lower peak action and longer TDA in cats.
The pharmacodynamics of Toujeo® and Lantus® were studied in 7 healthy neutered male cats, each receiving 0.8 U/kg SQ injection of each formulation on two different days, > 1 week apart, in random order. Pharmacodynamics were determined by the isoglycemic clamp method: blood glucose (BG) was measured every 5 min and glucose was administered intravenously at a variable rate, aiming for BG = 90% of baseline. Glucose infusion rate was used as a measure of exogenous insulin action. The Shapiro-Wilk test was used to assess normality. Normally distributed parameters were compared using paired t-tests.
There were no differences in total metabolic effect (ME), onset of action, or peak action. TDA (mean ± SD) of Toujeo® (16.8 ± 4.7h) was not significantly different than TDA of Lantus® (13.4h ± 2.6h, P = 0.2). In 6 cats the TDA of Toujeo® was longer by (median [range]) 4.8h [0.3–11.3h]) while in the seventh cat the TDA of Lantus® was longer (7.8h). The 12-24h post-injection ME fraction out of the 0-24h ME was (mean ± SD) 35% ± 23% for Toujeo® vs. 7% ± 8% for Lantus® (P = 0.048), indicating a more even distribution of ME over the 24h period.
The more even distribution of ME of Toujeo® over a 24h period, coupled with a TDA > 16h, makes Toujeo® more suitable for once-daily administration in cats.
Zusammenfassung: in gesunden Katzen, scheint Insulin Toujeo etwas laenger zu wirken als Lantus. Aber leider nicht >=24 Stunden lang, was eine einmal taegliche Spritze ermoeglichen wuerde. Aber es koennte sein, dass Toujeo etwas als gleichmaessiger wirkt. Jedoch duerfte die genaue Dosierung schwierig sein, da Toujeo 300 IE/ml hat.EN04 - Comparison of Pharmacodynamics Between Insulin Glargine 100U/mL and Insulin Glargine 300U/mL in Healthy Cats
Chen Gilor, DVM, PhD, DACVIM
Associate Professor, UC Davis, Davis, California
In people, insulin glargine (IGla) 300U/mL (Toujeo®) is associated with longer duration of action (TDA) and lesser within-day variability compared to IGla 100U/mL (Lantus®). We hypothesized that compared to Lantus®, Toujeo® would have a lower peak action and longer TDA in cats.
The pharmacodynamics of Toujeo® and Lantus® were studied in 7 healthy neutered male cats, each receiving 0.8 U/kg SQ injection of each formulation on two different days, > 1 week apart, in random order. Pharmacodynamics were determined by the isoglycemic clamp method: blood glucose (BG) was measured every 5 min and glucose was administered intravenously at a variable rate, aiming for BG = 90% of baseline. Glucose infusion rate was used as a measure of exogenous insulin action. The Shapiro-Wilk test was used to assess normality. Normally distributed parameters were compared using paired t-tests.
There were no differences in total metabolic effect (ME), onset of action, or peak action. TDA (mean ± SD) of Toujeo® (16.8 ± 4.7h) was not significantly different than TDA of Lantus® (13.4h ± 2.6h, P = 0.2). In 6 cats the TDA of Toujeo® was longer by (median [range]) 4.8h [0.3–11.3h]) while in the seventh cat the TDA of Lantus® was longer (7.8h). The 12-24h post-injection ME fraction out of the 0-24h ME was (mean ± SD) 35% ± 23% for Toujeo® vs. 7% ± 8% for Lantus® (P = 0.048), indicating a more even distribution of ME over the 24h period.
The more even distribution of ME of Toujeo® over a 24h period, coupled with a TDA > 16h, makes Toujeo® more suitable for once-daily administration in cats.
Ich wuerde mich freuen, wenn jemand hier Erfahrung mit diesem Insulin hat und sie beschreiben wuerde (Akromegalie-Miezen?).
Zuletzt bearbeitet: